Enhanced recovery in liver resection surgery

Enhanced recovery in liver resection surgery: a single-blinded randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN03274575

Enrollment

Registered

2011-07-28

Start date

2011-03-22

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver resection surgery Surgery Liver resection surgery

Interventions

Randomisation ? patients will be randomised into the IG or CG. Randomisation will be carried out by an independent statistician in the Department of Mathematics, University of Surrey. Concealment will

this is also what other surgical Event-Related Potentials (ERPs) have achieved. In order to determine (with a power of 80%, using a two-sided two-sample Student?s t-test), whether the IG group have a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All adult open elective liver resections

Exclusion criteria

Exclusion criteria: 1. Contraindications to epidural anaesthesia 2. Combined liver procedures e.g. with biliary surgery 3. Laparoscopic surgery 4. Adults unable to give informed consent

Design outcomes

Primary

Measure	Time frame
The post-operative length of stay (in days): two independent assessors (who will be blinded to group allocation) will assess whether the patient is ready to be discharged home. The patient will only be discharged from hospital if both assessors agree to discharge.	—

Secondary

Measure	Time frame
1. Quality of Life (using EQ-5D) 2. Patient satisfaction 3. Incidence of post-operative morbidity (using Post-Operative Morbidity Survey [POMS]) 4. Pain scores (Visual Analogue Score 0-10) 5. Stress response and cell-mediated immunity. The venous blood samples obtained from the patients will be analysed for the following: 5.1. Insulin, cortisol and glucose levels - to assess endocrine and metabolic response 5.2. C-reactive proteins (CRP) and cytokines (including interleukin [IL] 2, IL 4, IL 6, IL 8, IL 10, granulocyte-macrophage colony stimulating factor [GM-CSF], interferon gamma, tumour necrosis factor alpha) to assess the inflammatory response 5.3. T-cell markers (CD3, CD4, CD8, CD45RO, HLA-DR), natural killer (NK) cell markers (CD56, CD16) to assess the immune response	—

Measure

Time frame

1. Quality of Life (using EQ-5D) 2. Patient satisfaction 3. Incidence of post-operative morbidity (using Post-Operative Morbidity Survey [POMS]) 4. Pain scores (Visual Analogue Score 0-10) 5. Stress response and cell-mediated immunity. The venous blood samples obtained from the patients will be analysed for the following: 5.1. Insulin, cortisol and glucose levels - to assess endocrine and metabolic response 5.2. C-reactive proteins (CRP) and cytokines (including interleukin [IL] 2, IL 4, IL 6, IL 8, IL 10, granulocyte-macrophage colony stimulating factor [GM-CSF], interferon gamma, tumour necrosis factor alpha) to assess the inflammatory response 5.3. T-cell markers (CD3, CD4, CD8, CD45RO, HLA-DR), natural killer (NK) cell markers (CD56, CD16) to assess the immune response

—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 23, 2026